Kinder cuts: CRO deals palliate pharma downsizing
This article was originally published in Scrip
Executive Summary
Five years ago, pharma was in the throes of a vast cull as the global financial meltdown and the patent cliff combined to create a perfect storm for the industry. In 2009, more than 60,000 job cuts were announced in the sector in the US alone, according to the US outplacement specialist Challenger, Gray & Christmas.
You may also be interested in...
Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops
Takeda has chosen US-based PRA Health Sciences to lead its clinical development as part of the Japanese drug maker’s global R&D overhaul aimed at cutting costs and improving efficiency and innovation.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.